Both ex vivo and in vivo studies demonstrated that glutamine antagonism could skew CD8+ T cells toward an activated, long‐lived, memory‐like phenotype.[6] Furthermore, JHU083 has the ability to transform immune‐suppressive myeloid‐derived suppressor cells (MDSCs) and tumor‐associated macrophages (TAMs) into tumor‐destructive proinflammatory macrophages.[10] Interestingly, anti‐tumor effects were greatly diminished in immune‐deficient mice upon JHU083 treatment. Here, CD8A is linked to neoplasm.